{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:13:28Z","timestamp":1759882408307,"version":"build-2065373602"},"reference-count":32,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2025.15259","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T05:15:12Z","timestamp":1757049312000},"page":"1-6","source":"Crossref","is-referenced-by-count":0,"title":["Risks of haematological malignancies in patients treated for solid tumours associated with the use of pegylated granulocyte colony\u2011stimulating factors: A single centre study since 2005"],"prefix":"10.3892","volume":"30","author":[{"given":"Samuel","family":"Vokurka","sequence":"first","affiliation":[{"name":"Department of Oncology and Radiotherapeutics, Faculty of Medicine of Charles University in Pilsen, University Hospital in Pilsen, Charles University, 32300 Pilsen, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubo\u0161","family":"Mastn\u00fd","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiotherapeutics, Faculty of Medicine of Charles University in Pilsen, University Hospital in Pilsen, Charles University, 32300 Pilsen, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vojt\u011bch","family":"Kliment","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiotherapeutics, Faculty of Medicine of Charles University in Pilsen, University Hospital in Pilsen, Charles University, 32300 Pilsen, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Kulh\u00e1nkov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiotherapeutics, Faculty of Medicine of Charles University in Pilsen, University Hospital in Pilsen, Charles University, 32300 Pilsen, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Dreslerov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiotherapeutics, Faculty of Medicine of Charles University in Pilsen, University Hospital in Pilsen, Charles University, 32300 Pilsen, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terezie","family":"\u0160amanov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiotherapeutics, Faculty of Medicine of Charles University in Pilsen, University Hospital in Pilsen, Charles University, 32300 Pilsen, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jind\u0159ich","family":"F\u00ednek","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiotherapeutics, Faculty of Medicine of Charles University in Pilsen, University Hospital in Pilsen, Charles University, 32300 Pilsen, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"key":"key20251007110317_b1-ol-30-5-15259","first-page":"9877","article-title":"Supportive therapies in the prevention of chemotherapy-induced febrile neutropenia and appropriate use of granulocyte colony-stimulating factors: A Delphi consensus statement","volume":"30","author":"Adamo","year":"2022","journal-title":"Support Care Cancer"},{"key":"key20251007110317_b2-ol-30-5-15259","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony-stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro","year":"2011","journal-title":"Eur J Cancer"},{"key":"key20251007110317_b3-ol-30-5-15259","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO clinical practice guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann Oncol"},{"key":"key20251007110317_b4-ol-30-5-15259","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"key":"key20251007110317_b5-ol-30-5-15259","first-page":"277","article-title":"Blue Book of the Czech Oncology Society. Recommendation concerning the treatment of haematologic toxicities","author":"Igor","year":"2025","edition":"31st Edition"},{"key":"key20251007110317_b6-ol-30-5-15259","first-page":"3295","article-title":"Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: Consensus guidance recommendations","volume":"25","author":"Aapro","year":"2017","journal-title":"Support Care Cancer"},{"key":"key20251007110317_b7-ol-30-5-15259","doi-asserted-by":"publisher","first-page":"100038","DOI":"10.1016\/j.esmoop.2020.100038","article-title":"Supportive care in patients with cancer during the COVID-19 pandemic","volume":"6","author":"Aapro","year":"2021","journal-title":"ESMO Open"},{"key":"key20251007110317_b8-ol-30-5-15259","doi-asserted-by":"publisher","first-page":"18","DOI":"10.6004\/jnccn.2020.7610","article-title":"Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic","volume":"19","author":"Griffiths","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"key20251007110317_b9-ol-30-5-15259","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.ejca.2008.11.021","article-title":"Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis","volume":"45","author":"von Minckwitz","year":"2009","journal-title":"Eur J Cancer"},{"key":"key20251007110317_b10-ol-30-5-15259","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.critrevonc.2009.06.004","article-title":"Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy","volume":"74","author":"Aapro","year":"2010","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20251007110317_b11-ol-30-5-15259","doi-asserted-by":"publisher","first-page":"vi505","DOI":"10.1093\/annonc\/mdw390.27","article-title":"1457P - Prophylaxis of chemotherapy-induced neutropenia with lipegfilgrastim in patients with breast cancer: results from an interim analysis of the non-interventional study NADIR","volume":"27","author":"Kurbacher","year":"2016","journal-title":"Annals of Oncology"},{"key":"key20251007110317_b12-ol-30-5-15259","doi-asserted-by":"publisher","first-page":"VIII607","DOI":"10.1093\/annonc\/mdy300.014","article-title":"Use of lipegfilgrastim for the prophylaxis of chemotherapy-induced neutropenia: Pan-European non-interventional study","volume":"29","author":"Steger","year":"2018","journal-title":"Ann Oncol"},{"key":"key20251007110317_b13-ol-30-5-15259","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1186\/1471-2407-13-386","article-title":"Efficacy and safety of lipegfilgrastim versus pegfilgrastim: A randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin\/docetaxel chemotherapy","volume":"13","author":"Bondarenko","year":"2013","journal-title":"BMC Cancer"},{"key":"key20251007110317_b14-ol-30-5-15259","first-page":"395","article-title":"Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study","volume":"24","author":"Gladkov","year":"2016","journal-title":"Support Care Cancer"},{"key":"key20251007110317_b15-ol-30-5-15259","first-page":"2519","article-title":"Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): Results of the randomized, open-label, non-inferiority AVOID neutropenia study","volume":"29","author":"Link","year":"2021","journal-title":"Support Care Cancer"},{"key":"key20251007110317_b16-ol-30-5-15259","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1200\/JCO.2009.25.8723","article-title":"Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: A systematic review","volume":"28","author":"Lyman","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20251007110317_b17-ol-30-5-15259","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/jnci\/djk028","article-title":"Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy","volume":"99","author":"Hershman","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"key20251007110317_b18-ol-30-5-15259","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10549-015-3590-1","article-title":"Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer","volume":"154","author":"Calip","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"key20251007110317_b19-ol-30-5-15259","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/ijc.33216","article-title":"Risk of secondary hematologic malignancies associated with breast cancer chemotherapy and G-CSF support: A nationwide population-based cohort","volume":"148","author":"Jabagi","year":"2021","journal-title":"Int J Cancer"},{"key":"key20251007110317_b20-ol-30-5-15259","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1093\/annonc\/mdy311","article-title":"Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support","volume":"29","author":"Lyman","year":"2018","journal-title":"Ann Oncol"},{"key":"key20251007110317_b21-ol-30-5-15259","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-023-00776-9","article-title":"Mitigating long-term and delayed adverse events associated with cancer treatment: Implications for survivorship","volume":"20","author":"Lustberg","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"key20251007110317_b22-ol-30-5-15259","doi-asserted-by":"publisher","first-page":"e187147","DOI":"10.1001\/jamanetworkopen.2018.7147","article-title":"Evaluation of the incidence of hematologic malignant neoplasms among breast cancer survivors in France","volume":"2","author":"Jabagi","year":"2019","journal-title":"JAMA Network Open"},{"key":"key20251007110317_b23-ol-30-5-15259","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.3390\/ijerph9062075","article-title":"Mechanism of generation of therapy related leukemia in response to anti-topoisomerase II agents","volume":"9","author":"Cowell","year":"2012","journal-title":"Int J Environ Res Public Health"},{"key":"key20251007110317_b24-ol-30-5-15259","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJM199902043400504","article-title":"Risk of leukemia after platinum-based chemotherapy for ovarian cancer","volume":"340","author":"Travis","year":"1999","journal-title":"N Engl J Med"},{"key":"key20251007110317_b25-ol-30-5-15259","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/cncr.31144","article-title":"Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients","volume":"124","author":"Rosenstock","year":"2018","journal-title":"Cancer"},{"key":"key20251007110317_b26-ol-30-5-15259","first-page":"4140","article-title":"Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy","volume":"5","author":"Patel","year":"2021","journal-title":"Blood Adv"},{"key":"key20251007110317_b27-ol-30-5-15259","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s10549-012-2386-9","article-title":"Risk of myelodysplastic syndrome and acute myeloid leukemia post radiation treatment for breast cancer: A population-based study","volume":"137","author":"Kaplan","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"key20251007110317_b28-ol-30-5-15259","doi-asserted-by":"publisher","first-page":"14297","DOI":"10.1038\/s41598-020-71386-z","article-title":"Prevalence and clinical implications of germline predisposition gene mutations in patients with acute myeloid leukemia","volume":"10","author":"Kim","year":"2020","journal-title":"Sci Rep"},{"key":"key20251007110317_b29-ol-30-5-15259","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3324\/haematol.12234","article-title":"Cancer risks in Fanconi anemia: Findings from the German Fanconi Anemia Registry","volume":"93","author":"Rosenberg","year":"2008","journal-title":"Haematologica"},{"key":"key20251007110317_b30-ol-30-5-15259","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1182\/blood.2022015790","article-title":"Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages","volume":"140","author":"Feurstein","year":"2022","journal-title":"Blood"},{"key":"key20251007110317_b31-ol-30-5-15259","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1080\/10428194.2018.1551539","article-title":"PALB2 variant status in hematological malignancies-a potential therapeutic target?","volume":"60","author":"Oldreive","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"key20251007110317_b32-ol-30-5-15259","doi-asserted-by":"publisher","first-page":"7155","DOI":"10.1073\/pnas.0811159106","article-title":"PALB2 is an integral component of the BRCA complex required for homologous recombination repair","volume":"106","author":"Sy","year":"2009","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T08:04:21Z","timestamp":1759824261000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2025.15259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,9,5]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2025.15259","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"type":"print","value":"1792-1074"},{"type":"electronic","value":"1792-1082"}],"subject":[],"published":{"date-parts":[[2025,9,5]]}}}